PT  - JOURNAL ARTICLE
AU  - Keeton, Roanne
AU  - Richardson, Simone I.
AU  - Moyo-Gwete, Thandeka
AU  - Hermanus, Tandile
AU  - Tincho, Marius B.
AU  - Benede, Ntombi
AU  - Manamela, Nelia P.
AU  - Baguma, Richard
AU  - Makhado, Zanele
AU  - Ngomti, Amkele
AU  - Motlou, Thopisang
AU  - Mennen, Mathilda
AU  - Chinhoyi, Lionel
AU  - Skelem, Sango
AU  - Maboreke, Hazel
AU  - Doolabh, Deelan
AU  - Iranzadeh, Arash
AU  - Otter, Ashley D.
AU  - Brooks, Tim
AU  - Noursadeghi, Mahdad
AU  - Moon, James
AU  - Grifoni, Alba
AU  - Weiskopf, Daniela
AU  - Sette, Alessandro
AU  - Blackburn, Jonathan
AU  - Hsiao, Nei-Yuan
AU  - Williamson, Carolyn
AU  - Riou, Catherine
AU  - Goga, Ameena
AU  - Garrett, Nigel
AU  - Bekker, Linda-Gail
AU  - Gray, Glenda
AU  - Ntusi, Ntobeko A. B.
AU  - Moore, Penny L.
AU  - Burgers, Wendy A.
TI  - Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner
AID  - 10.1101/2021.07.24.21261037
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.24.21261037
4099  - http://medrxiv.org/content/early/2021/09/29/2021.07.24.21261037.short
4100  - http://medrxiv.org/content/early/2021/09/29/2021.07.24.21261037.full
AB  - The Johnson and Johnson Ad26.COV2.S single dose vaccine represents an attractive option for COVID-19 vaccination in resource limited countries. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naïve with those either infected with the ancestral D614G virus, or infected in the second wave when Beta predominated. Prior infection significantly boosted spike binding antibodies, antibody-dependent cellular cytotoxicity and neutralizing antibodies against D614G, Beta and Delta, however neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses were induced after vaccination, regardless of prior infection. T cell recognition of variants was largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination following infection may result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the South African Medical Research Council (SA-MRC) with funds received from the South African Department of Science and Innovation, including grants 96825, SHIPNCD 76756 and DST/CON 0250/2012. This work was also supported by the Poliomyelitis Research Foundation (21/65) and the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core funding from the Wellcome Trust (203135/Z/16/Z and 222754). P.L.M. and S.I.R. are supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation (NRF; Grant No 9834). S.I.R. is a LOreal/UNESCO Women in Science South Africa Young Talents awardee. W.A.B. and C.R. are supported by the EDCTP2 programme of the European Unions Horizon 2020 programme (TMA2017SF-1951-TB-SPEC to C.R. and TMA2016SF-1535-CaTCH-22 to W.A.B.). N.A.B.N acknowledges funding from the SA-MRC, MRC UK, NRF and the Lily and Ernst Hausmann Trust. M.N. is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to University College London Hospitals.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Cape Town Human Research Ethics Committee (HREC 190/2020 and 209/2020) and the University of the Witwatersrand Human Research Ethics Committee (Medical) (no M210429).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available in the manuscript or Supplementary files.